Background CSF and PET biomarkers of amyloid β and tau accurately detect Alzheimer's
disease pathology, but the invasiveness, high cost, and poor availability of these detection …

Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer’s
disease are needed to facilitate the initial screening process of participants in disease-…

Whilst cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers for
amyloid-β (Aβ) and tau pathologies are accurate for the diagnosis of Alzheimer’s disease (AD), …

The neuropathological confirmation of amyloid-β (Aβ) plaques and tau neurofibrillary
tangles (NFT) remains the gold standard for a definitive diagnosis of Alzheimer’s disease (AD). …

In Alzheimer’s disease (AD), tau phosphorylation in the brain and its subsequent release
into cerebrospinal fluid (CSF) and blood is a dynamic process that changes during disease …

Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or
plasma, has shown great promise in detecting Alzheimer’s disease (AD) pathophysiology. Tau …

Gold-standard diagnosis of Alzheimer’s disease (AD) relies on histopathological staging
systems. Using the topographical information from [ 18 F]MK6240 tau positron-emission …

Introduction This study investigated the diagnostic and disease‐monitoring potential of plasma
biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia …

Plasma biomarkers related to amyloid, tau, and neurodegeneration (ATN) show great
promise for identifying these pathological features of Alzheimer’s Disease (AD) as shown by …